The Global Canine Arthritis Treatment Market was valued at USD 3.8 billion in 2025 and is estimated to grow at a CAGR of 7.8% to reach USD 7.9 billion by 2035.
The market expansion is driven by the rising incidence of osteoarthritis (OA) in dogs. Canine arthritis treatment encompasses a range of therapies designed to manage joint pain, inflammation, and reduced mobility in dogs affected by osteoarthritis or other degenerative joint disorders. These treatments aim to alleviate discomfort, restore joint function, and improve overall well-being through individualized, multimodal approaches that match disease severity and the dog’s specific needs. Options include pharmaceutical interventions such as NSAIDs, corticosteroids, and opioid pain relievers, along with newer biologic therapies like monoclonal antibodies, nutritional supplements including glucosamine and omega-3 fatty acids, physical therapy, and, in certain cases, surgical procedures. Adoption of multimodal treatment strategies has strengthened market growth, as combining medications, supplements, and physical therapies provides more comprehensive management for long-term joint health and improved mobility in dogs.
In 2025, the non-surgical treatments segment held a 77.1% share, generating USD 2.9 billion. This dominance reflects the growing preference among pet owners and veterinarians for non-invasive therapies, such as pharmaceuticals, monoclonal antibodies, supplements, and physical rehabilitation, before considering surgical intervention. Non-surgical approaches are also more cost-effective and accessible for managing chronic conditions over the long term. Increased awareness of disease prevention and the importance of slowing arthritis progression is encouraging broader adoption of these therapies among pet populations worldwide.
The osteoarthritis segment held 56.9% share in 2025. Osteoarthritis is one of the most common degenerative joint disorders in dogs, contributing significantly to the overall burden of canine arthritis. Rising OA prevalence across age groups emphasizes the need for effective, long-term management strategies, positioning osteoarthritis as the dominant segment in the canine arthritis treatment market.
North America Canine Arthritis Treatment Market accounted for 43.3% share in 2025. Market growth in this region is fueled by high pet ownership rates, substantial spending on veterinary care, and advanced veterinary infrastructure. A strong network of clinics, specialty hospitals, and diagnostic centers ensures early diagnosis and continuous management of chronic conditions such as arthritis. North American pet owners’ willingness to invest in innovative treatments further drives the adoption of multimodal therapies and high-quality veterinary products.
Key players in the Global Canine Arthritis Treatment Market include Zoetis, VetriScience, Elanco Animal Health, Boehringer Ingelheim Animal Health, K9 Vitality, Dechra Pharmaceuticals, CEVA Santé Animale, Norbrook Laboratories, Nutramax Laboratories Veterinary Sciences, VetStem, Thorne Vet, Auburn Laboratories, Virbac, AdvaCare Pharma, Deley Naturals, American Regent, and JBT Corporation. Leading companies in the canine arthritis treatment market are implementing a range of strategies to strengthen their position and expand their market footprint. They are heavily investing in research and development to introduce innovative pharmaceuticals, biologics, and nutritional supplements tailored for canine joint health. Strategic partnerships with veterinary clinics, specialty hospitals, and distributors are being established to expand market access and provide localized support. Companies are also focusing on acquiring smaller firms with complementary technologies, allowing rapid portfolio expansion and entry into new geographies.
This product will be delivered within 2-4 business days.
The market expansion is driven by the rising incidence of osteoarthritis (OA) in dogs. Canine arthritis treatment encompasses a range of therapies designed to manage joint pain, inflammation, and reduced mobility in dogs affected by osteoarthritis or other degenerative joint disorders. These treatments aim to alleviate discomfort, restore joint function, and improve overall well-being through individualized, multimodal approaches that match disease severity and the dog’s specific needs. Options include pharmaceutical interventions such as NSAIDs, corticosteroids, and opioid pain relievers, along with newer biologic therapies like monoclonal antibodies, nutritional supplements including glucosamine and omega-3 fatty acids, physical therapy, and, in certain cases, surgical procedures. Adoption of multimodal treatment strategies has strengthened market growth, as combining medications, supplements, and physical therapies provides more comprehensive management for long-term joint health and improved mobility in dogs.
In 2025, the non-surgical treatments segment held a 77.1% share, generating USD 2.9 billion. This dominance reflects the growing preference among pet owners and veterinarians for non-invasive therapies, such as pharmaceuticals, monoclonal antibodies, supplements, and physical rehabilitation, before considering surgical intervention. Non-surgical approaches are also more cost-effective and accessible for managing chronic conditions over the long term. Increased awareness of disease prevention and the importance of slowing arthritis progression is encouraging broader adoption of these therapies among pet populations worldwide.
The osteoarthritis segment held 56.9% share in 2025. Osteoarthritis is one of the most common degenerative joint disorders in dogs, contributing significantly to the overall burden of canine arthritis. Rising OA prevalence across age groups emphasizes the need for effective, long-term management strategies, positioning osteoarthritis as the dominant segment in the canine arthritis treatment market.
North America Canine Arthritis Treatment Market accounted for 43.3% share in 2025. Market growth in this region is fueled by high pet ownership rates, substantial spending on veterinary care, and advanced veterinary infrastructure. A strong network of clinics, specialty hospitals, and diagnostic centers ensures early diagnosis and continuous management of chronic conditions such as arthritis. North American pet owners’ willingness to invest in innovative treatments further drives the adoption of multimodal therapies and high-quality veterinary products.
Key players in the Global Canine Arthritis Treatment Market include Zoetis, VetriScience, Elanco Animal Health, Boehringer Ingelheim Animal Health, K9 Vitality, Dechra Pharmaceuticals, CEVA Santé Animale, Norbrook Laboratories, Nutramax Laboratories Veterinary Sciences, VetStem, Thorne Vet, Auburn Laboratories, Virbac, AdvaCare Pharma, Deley Naturals, American Regent, and JBT Corporation. Leading companies in the canine arthritis treatment market are implementing a range of strategies to strengthen their position and expand their market footprint. They are heavily investing in research and development to introduce innovative pharmaceuticals, biologics, and nutritional supplements tailored for canine joint health. Strategic partnerships with veterinary clinics, specialty hospitals, and distributors are being established to expand market access and provide localized support. Companies are also focusing on acquiring smaller firms with complementary technologies, allowing rapid portfolio expansion and entry into new geographies.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Treatment Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Arthritis Type, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The companies profiled in this Canine Arthritis Treatment market report include:- AdvaCare Pharma
- American Regent
- Auburn Laboratories
- Boehringer Ingelheim Animal Health
- CEVA Santé Animale
- Dechra Pharmaceuticals
- Deley Naturals
- Elanco Animal Health
- K9 Vitality
- Norbrook Laboratories
- Nutramax Laboratories Veterinary Sciences
- Thorne Vet
- Vetoquinol
- VetriScience
- VetStem
- Virbac
- Zoetis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 148 |
| Published | January 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 3.8 Billion |
| Forecasted Market Value ( USD | $ 7.9 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
